RT Journal Article
SR Electronic
T1 Predicting Post-operative Pain in Lung Cancer Patients using Pre-operative Peak Alpha Frequency
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.25.21266863
DO 10.1101/2021.11.25.21266863
A1 Millard, Samantha K.
A1 Furman, Andrew J.
A1 Kerr, Amy
A1 Seminowicz, David A.
A1 Gao-Smith, Fang
A1 Naidu, Babu V.
A1 Mazaheri, Ali
YR 2021
UL http://medrxiv.org/content/early/2021/11/26/2021.11.25.21266863.abstract
AB Aims and Objectives Experimental models of neuropathic pain suggest that individual peak alpha frequency (PAF), measured using electroencephalography (EEG), can predict future pain sensitivity in experimental settings. Here, we tested whether PAF could predict future pain severity in a clinical setting in patients undergoing thoracotomy.Methods Recorded using wearable around the ear electrodes (cEEGrids), the feasibility and efficacy of pre-operative PAF as a neuro-marker for post-operative pain was assessed in 16 patients undergoing thoracic surgery for lung cancer (age = 67.53 ± 4.38 [SD]). Patients also provided numerical ratings (0-10) of current, average, and worst pain pre-operatively as well as within three days post-operativelyResults and Significance Pre-operative PAF of less than 9 Hz was highly sensitive (1.0) and specific (0.86) in identifying patients who would go on to experience severe (>7/10) worst pain. Moreover, PAF was negatively correlated with patients’ current, average, and worst post-operative pain. PAF was significantly higher for those reporting lower pain severity compared to those reporting higher pain severity in the immediate post-operative period. This suggests that PAF is a promising neuro-marker to pre-operatively assess individual susceptibility to severe pain in the immediate post-operative period, possibly enabling more informed assessment of an individual’s suitability for surgery.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by a seed grant from Experimental Medicine Cancer Centre (EMCM) Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data were collected as part of a larger prospective research project examining the effects of a rehabilitation programme on postoperative complications in patients undergoing surgery for lung cancer,Rehabilitation for Operated lung cancer (ROC). The ROC project was approved by the NHS ethics (Reference: 10/H1208/41).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors